(QURE) Uniqure - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.799m USD | Total Return: 59.2% in 12m

Gene Therapies, Rare Disease Treatments, Biopharmaceuticals
Total Rating 41
Safety 35
Buy Signal 0.56
Biotechnology
Industry Rotation: -6.9
Market Cap: 1.80B
Avg Turnover: 38.8M
Risk 3d forecast
Volatility162%
VaR 5th Pctl16.5%
VaR vs Median-65.1%
Reward TTM
Sharpe Ratio0.87
Rel. Str. IBD95
Rel. Str. Peer Group83.8
Character TTM
Beta2.573
Beta Downside1.133
Hurst Exponent0.442
Drawdowns 3y
Max DD87.21%
CAGR/Max DD0.12
CAGR/Mean DD0.19
EPS (Earnings per Share) EPS (Earnings per Share) of QURE over the last years for every Quarter: "2021-06": 7.23, "2021-09": -0.68, "2021-12": 0.17, "2022-03": -0.95, "2022-06": -0.83, "2022-09": -1.03, "2022-12": 0.15, "2023-03": -1.48, "2023-06": -1.31, "2023-09": -1.75, "2023-12": -1.53, "2024-03": -1.26, "2024-06": -1.08, "2024-09": -0.84, "2024-12": -1.4415, "2025-03": -0.73, "2025-06": -0.6, "2025-09": -1.19, "2025-12": -0.4739, "2026-03": -0.73,
Last SUE: 0.05
Qual. Beats: 0
Revenue Revenue of QURE over the last years for every Quarter: 2021-06: 463.868, 2021-09: 1.989, 2021-12: 57.691, 2022-03: 1.792, 2022-06: 0.497, 2022-09: 1.449, 2022-12: 102.745, 2023-03: 5.325, 2023-06: 2.422, 2023-09: 1.407, 2023-12: 6.689, 2024-03: 8.485, 2024-06: 11.126, 2024-09: 2.287, 2024-12: 5.221, 2025-03: 1.567, 2025-06: 5.262, 2025-09: 3.701, 2025-12: 5.568, 2026-03: 3.562,
Rev. CAGR: -42.80%
Rev. Trend: -70.3%
Last SUE: -0.19
Qual. Beats: 0

Warnings

Share dilution 28.6% YoY

Interest Coverage Ratio -2.8 is critical

Beneish M-Score 0.29 > -1.5 - likely earnings manipulation

Altman Z'' -2.48 < 1.0 - financial distress zone

Below Avwap Earnings

Tailwinds

Rs Leader, Idiosyncratic Leader, Confidence

Description: QURE Uniqure

uniQure N.V. (QURE) is a biotechnology company specializing in the development of gene therapies for rare and devastating diseases. Its commercial portfolio includes HEMGENIX, a treatment for hemophilia B, while its clinical pipeline focuses on central nervous system and metabolic disorders. The companys lead candidate, AMT-130, is currently in Phase I/II trials for Huntington’s disease, alongside several early-stage programs for epilepsy, ALS, and Fabry disease.

The gene therapy sector operates under a high-intensity R&D model where companies utilize viral vectors to deliver functional genes into a patients cells to treat the underlying cause of genetic conditions. Unlike traditional pharmaceuticals that require chronic dosing, gene therapies are often designed as one-time curative treatments, which commands a premium pricing structure and specialized manufacturing requirements.

Strategic partnerships are central to the business model; uniQure maintains licensing and supply agreements with CSL Behring and Apic Bio to facilitate global commercialization and production. For a deeper analysis of these clinical milestones and valuation metrics, consult ValueRay. The company remains headquartered in Amsterdam, focusing on advancing its proprietary technology platform through rigorous clinical study phases.

Headlines to Watch Out For
  • Hemgenix royalty and milestone payments from CSL Behring drive immediate revenue growth
  • Clinical data readouts for AMT-130 determine long-term valuation in Huntington’s disease
  • Pipeline expansion into epilepsy and ALS increases R&D expenditure and capital requirements
  • Regulatory approval timelines for gene therapy candidates impact future market exclusivity
  • High cash burn rates necessitate strategic partnerships or dilutive secondary equity offerings
Piotroski VR-10 (Strict) 1.0
Net Income: -208.9m TTM > 0 and > 6% of Revenue
FCF/TA: -0.24 > 0.02 and ΔFCF/TA 8.08 > 1.0
NWC/Revenue: 3.08k% < 20% (prev 1.98k%; Δ 1.10k% < -1%)
CFO/TA -0.22 > 3% & CFO -172.1m > Net Income -208.9m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 10.40 > 1.5 & < 3
Outstanding Shares: last quarter (62.7m) vs 12m ago 18.14% < -2%
Gross Margin: 74.14% > 18% (prev 53.97%; Δ 20.17% > 0.5%)
Asset Turnover: 2.61% > 50% (prev 3.34%; Δ -0.72% > 0%)
Interest Coverage Ratio: -2.76 > 6 (EBIT TTM -168.1m / Interest Expense TTM 60.9m)
Altman Z'' -2.48
A: 0.71 (Total Current Assets 615.7m - Total Current Liabilities 59.2m) / Total Assets 778.7m
B: -1.78 (Retained Earnings -1.38b / Total Assets 778.7m)
C: -0.24 (EBIT TTM -168.1m / Avg Total Assets 692.1m)
D: 0.24 (Book Value of Equity 149.3m / Total Liabilities 629.4m)
Altman-Z'' = -2.48 = D
Beneish M 0.29
DSRI: 5.58 (Receivables 12.6m/2.52m, Revenue 18.1m/20.2m)
GMI: 0.73 (GM 53.97% / 74.14%)
AQI: 0.78 (AQ_t 0.18 / AQ_t-1 0.23)
SGI: 0.90 (Revenue 18.1m / 20.2m)
TATA: -0.05 (NI -208.9m - CFO -172.1m) / TA 778.7m)
Beneish M = 0.29 (Cap -4..+1) = D
What is the price of QURE shares?

As of June 06, 2026, the stock is trading at USD 26.45 with a total of 1,447,472 shares traded.
Over the past week, the price has changed by -7.29%, over one month by +25.00%, over three months by +148.36% and over the past year by +59.24%.

Is QURE a buy, sell or hold?

Uniqure has received a consensus analysts rating of 4.54. Therefore, it is recommended to buy QURE.

  • StrongBuy: 9
  • Buy: 2
  • Hold: 2
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the QURE price?
Analysts Target Price 39.2 48.3%
Uniqure (QURE) - Fundamental Data Overview as of 31 May 2026
Market Cap USD = 1.80b (1.80b USD * 1.0 USD.USD)
P/E Forward = 27.933
P/S = 87.7361
P/B = 10.6208
Revenue TTM = 18.1m USD
EBIT TTM = -168.1m USD
EBITDA TTM = -154.9m USD
Long Term Debt = 49.9m USD (from longTermDebt, last quarter)
Short Term Debt = 2.99m USD (from shortTermDebt, last quarter)
Debt = 76.7m USD (from shortLongTermDebtTotal, last quarter) + Leases 13.4m
Net Debt = -136.0m USD (calculated: Debt 76.7m - CCE 212.7m)
Enterprise Value = 1.66b USD (1.80b + Debt 76.7m - CCE 212.7m)
Interest Coverage Ratio = -2.76 (Ebit TTM -168.1m / Interest Expense TTM 60.9m)
EV/FCF = -8.97x (Enterprise Value 1.66b / FCF TTM -185.4m)
FCF Yield = -11.14% (FCF TTM -185.4m / Enterprise Value 1.66b)
 FCF Margin = -1.02k% (FCF TTM -185.4m / Revenue TTM 18.1m)
 Net Margin = -1.15k% (Net Income TTM -208.9m / Revenue TTM 18.1m)
 Gross Margin = 74.14% ((Revenue TTM 18.1m - Cost of Revenue TTM 4.68m) / Revenue TTM)
Gross Margin QoQ = 93.85% (prev 38.85%)
Tobins Q-Ratio = 2.14 (Enterprise Value 1.66b / Total Assets 778.7m)
 Interest Expense / Debt = 79.42% (Interest Expense 60.9m / Debt 76.7m)
 Taxrate = 21.0% (US federal default 21%)
NOPAT = -132.8m (EBIT -168.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 9.68 (Total Current Assets 615.7m / Total Current Liabilities 63.6m)
Debt / Equity = 0.51 (Debt 76.7m / totalStockholderEquity, last quarter 149.3m)
 Debt / EBITDA = 0.88 (negative EBITDA) (Net Debt -136.0m / EBITDA -154.9m)
 Debt / FCF = 0.73 (negative FCF - burning cash) (Net Debt -136.0m / FCF TTM -185.4m)
 Total Stockholder Equity = 143.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -30.18% (Net Income -208.9m / Total Assets 778.7m)
RoE = -145.8% (Net Income TTM -208.9m / Total Stockholder Equity 143.2m)
RoCE = -86.99% (EBIT -168.1m / Capital Employed (Equity 143.2m + L.T.Debt 49.9m))
 RoIC = -18.40% (negative operating profit) (NOPAT -132.8m / Invested Capital 721.6m)
 WACC = 14.42% (E(1.80b)/V(1.88b) * Re(15.03%) + (debt cost/tax rate unavailable))
Discount Rate = 15.03% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 93.09 | Cagr: 12.85%
 [DCF] Fair Price = unknown (Cash Flow -185.4m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.05 | # QB: 0
Revenue Correlation: -70.27 | Revenue CAGR: -42.80% | SUE: -0.19 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.72 | Chg30d=+5.68% | Revisions=+50% | Analysts=10
EPS next Quarter (2026-09-30): EPS=-0.75 | Chg30d=+4.97% | Revisions=+23% | Analysts=10
EPS current Year (2026-12-31): EPS=-2.99 | Chg30d=-0.54% | Revisions=+0% | GrowthEPS=-2.2% | GrowthRev=+43.2%
EPS next Year (2027-12-31): EPS=-2.44 | Chg30d=-4.51% | Revisions=+8% | GrowthEPS=+18.6% | GrowthRev=+232.2%
[Analyst] Revisions Ratio: +50%